Novo Nordisk is dropping its full name in favor of a simpler brand identity as it battles Eli Lilly for dominance in weight loss and diabetes treatments. The company will now operate as Novo, keeping its iconic Apis bull logo but shedding the “Nordisk” from its public face. The move is part of a broader push to sharpen focus, speed up decision-making, and regain market momentum after years of slowing growth.
The rebrand coincides with a shift in corporate culture, dubbed The Novo Way, built around four principles: customer obsession, competitiveness, clarity, and care & integrity. Details will be unveiled at Novo’s capital markets day in London on September 21. The company’s tagline, “Lasting Health Starts Now”, reflects its urgency to address challenges in its core business—particularly the rise of Lilly’s dual-agonist drugs Zepbound and Mounjaro, which have outpaced Novo’s Wegovy and Ozempic in revenue growth.
Novo’s oral Wegovy has shown early promise against Lilly’s Foundayo, but the company’s pipeline has faced setbacks. A failed late-stage trial for its IL-6 inhibitor ziltivekimab in heart failure and atherosclerosis, along with disappointing results for its next-gen therapy CagriSema, have complicated its efforts to diversify beyond GLP-1 agonists. Meanwhile, the loss of patent exclusivity for semaglutide looms, with key markets like India already off-patent and China, Europe, and the U.S. expected to follow in the early 2030s.
Read Also: AbbVie tests new approach for menstrual migraine treatment
CEO Mike Doustdar, hired last year to reverse a period of declining share prices, framed the rebrand as a way to make healthcare more accessible and responsive. “Our brand and culture are strategically important,” he said, “but the reason we exist will not change.” The company insists its focus on lasting health remains unchanged, though the shift to Novo signals a deliberate attempt to streamline its image amid intensifying competition.
The rebrand’s success will hinge on whether the company can translate its new identity into tangible results. Lilly’s aggressive expansion into dual-agonist therapies has already reshaped the market, and Novo’s oral Wegovy must prove it can hold its own. With patent cliffs on the horizon and pipeline risks lingering, the company’s ability to execute on its “Novo Way” will determine whether the rebrand is more than a symbolic move, or a turning point.
